American Society of Clinical Oncology (ASCO) Recognizes TCGA’s Importance in the Past Decade and in Tumor Biology
April 13, 2015, by Emma J. Spaulding, M.P.H.
The Cancer Genome Atlas (TCGA) was identified as an important advance in the past decade of research by the American Society of Clinical Oncology (ASCO). The article, "Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology" cites TCGA as the first and most comprehensive undertaking of its kind and states that this research is providing essential data that can help to improve patient outcomes.
TCGA’s Pan-Cancer research was named as a "Top Advance in Tumor Biology" because it establishes that tumors from the same tissue of origin may be different from each other in important ways. This research may eventually help patients be matched to a drug targeted to their cancer subtype, which is an important component in precision medicine.